Newly-approved therapy provides improved quality of life for midgut neuroendocrine tumor patients

(H. Lee Moffitt Cancer Center& Research Institute) The Journal of Clinical Oncology published new data from the NETTER-1 clinical trial highlighting the impact of Lutathera on patients' quality of life. The results showed that treatment with Lutathera provides significantly longer time to deterioration of quality of life for patients compared to those treated with octreotide LAR alone.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news